Study details
Enrolling now
Safety and Tolerability of Fb-PMT in Recurrent Glioblastoma
NanoPharmaceuticals LLC
NCT IDNCT05226494ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
34
Study length
about 5.4 years
Ages
18+
Locations
1 site in CT
What this study is about
This trial is testing the safety and how well fb-PMT is tolerated in people with recurrent glioblastoma. The goal is to find a safe dose level for further development of fb-PMT as a treatment option.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take fb-PMT
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
Standard assignment
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Endpoints
Primary: Incidence of Dose Limiting Toxicities [Safety and Tolerability], Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]